SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Highly effective preservation solutions ensuring the safety and protection of personal care products
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Subscribe To Our Newsletter & Stay Updated
